Tuesday Educational Symposia during the ISPOR 11th European Congress

Tuesday 11 November 2008, 7:00-8:00

The Do’s and Don’ts with Agencies like NICE or IQWiG – Generating the Right Health Economic Data for Successful Appraisals

This symposium will give insights into what data NICE or IQWIG are looking for during HTA appraisals. Attendees will also receive guidance on how best to prepare their HTA dossier, and how clinical and health economic NHS data can support this.

HOW TO GATHER THE RIGHT HEALTH ECONOMIC DATA WITHIN THE NHS - A NOVEL APPROACH
Andreas Guhl PhD, Head of Health Outcomes Unit, NHS Innovations London, London, UK

GATHERING THE RIGHT DATA FOR SUCCESSFUL NICE APPRAISALS
Meindert Boysen PharmD MSc, Associate Director, Single Technology Appraisal, NICE, Manchester, UK.

GATHERING THE RIGHT DATA FOR SUCCESSFUL IQWIG APPRAISALS
J.Jaime Caro MDCM, FRCPC, FACOP, Chair of Expert Committee advising Institute for Quality and Efficiency in Health Care (IQWiG), Lexington, MA, USA

Sponsored by NHS Innovations London

Tuesday Educational Symposia during the ISPOR 11th European Congress

Tuesday 11 November 2008, 11:45-12:45

Personalized Medicine and Targeted Therapy -
Who Will Pay for Advances in Cancer Care?

The lifetime risk of developing cancer is approximately one in three, and will reach one in two in the near future. One in eight deaths are caused by cancer. With increased life expectancy, cancer is also becoming a major health care problem also in developing countries. Oncology is the focus of intense research and drug development; the number of oncology drugs in development (phase II and later) are more then all other therapeutic areas combined. Advances in diagnosis and therapy bring hope of turning incurable and fatal diseases into chronic but manageable conditions or even curing or preventing them altogether. Scientific progress is incremental; with each step the therapeutic value of a new medical innovation should be weighted against its cost and against alternative uses of limited health care resources. The development of targeted therapy has already impacted the treatment of some cancers (e.g. CML, breast-, colorectal- and lung cancer). Combination with diagnostic methods (cytology, pathology and functional imaging) for predicting which patients will benefit from treatment can improve both clinical outcomes and cost-effectiveness. 

This symposium will discuss the difficult challenges for industry, health care systems and societies worldwide in providing access to new cancer therapies in an environment of budget restrictions and pressures for cost containment.

Moderator: Michael Drummond PhD, Professor, University of York, York, UK

THE MEDICAL AND ECONOMIC CHALLENGES OF TARGETED THERAPY
Nils Wilking MD PhD, Associate Professor, Karolinska Institutet, Stockholm, Sweden

LINKING BIOMARKERS AND DRUGS FOR PERSONALIZED MEDICINE IN ONCOLOGY: AN ECONOMIC PERSPECTIVE ON THE CHALLENGES
Lou Garrison PhD, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA

THE SWEDISH CANCER STRATEGY PLAN
Rickard Bergström, Director General, LIF - Swedish Pharmaceutical Industry Association, Stockholm, Sweden.

                  

Sponsored by i3 Innovus